Within oncological contexts, CIITA augments tumor cell recognition by the immune system through upregulation of MHC II surface molecules, thereby facilitating efficient antigen presentation to CD4+ T lymphocytes 11-13. The gene discussed is CD4; the disease is neoplasm.